Share on LinkedInShare on LinkedIn

ARTICLE · 08 OCTOBER 2008

Federal Circuit Elaborates On Declaratory Judgment Jurisdiction Analysis In A Post-Medimmune World

In the latest of a series of post-MedImmune decisions regarding jurisdiction over declaratory judgment actions in patent cases, the U.S. Court of Appeals for the Federal Circuit further delineated the subtle borderland between jurisdiction and lack thereof.

United StatesIntellectual Property

In the latest of a series of post-MedImmune decisions regarding jurisdiction over declaratory judgment actions in patent cases, the U.S. Court of Appeals for the Federal Circuit further delineated the subtle borderland between jurisdiction and lack thereof. Prasco, LLC v. Medicis Pharmaceutical Corp., Case No. 07-1524, (Fed. Cir., Aug. 15, 2008) (Gajarsa, J.).

The manufacturer of a generic benzoyl peroxide product attempted to bring a declaratory judgment action for non-infringement of four patents that were marked on a competitor's benzoyl peroxide product. The generic manufacturer had not been sued for infringement on these patents nor had it been threatened or approached for a license. The manufacturer based its claim of jurisdiction simply upon the fact that its competitor marked the product with the four patents, had sued Prasco previously on an unrelated patent and a different product and had not signed a covenant not to sue on the four patents in question.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from